Harold E. "Barry" Selick, Ph.D.

Chief Executive Officer

Harold E. "Barry" Selick, Ph.D. joined Threshold as Chief Executive Officer in June 2002. Between June 2002 and July 2007, Dr. Selick was a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for treating kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.


TILLMAN PEARCE, M.D.

CHIEF MEDICAL OFFICER

Tillman Pearce, M.D. joined Threshold as Chief Medical Officer in February 2012. From April 2007 until March 2011, Dr. Pearce served as Chief Medical Officer at KaloBios Pharmaceuticals, Inc. Dr. Pearce has approximately 15 years of experience in the biopharmaceutical industry in both Europe and the United States. Prior to joining KaloBios, he was at Protein Design Labs in Paris, France, where he held the position Senior Director, Clinical Research and directed their European office. Between 1997 and 2002, Dr. Pearce was Medical Director at Sanofi-Synthelabo, S.A. in Paris, France, in their Oncology Business Unit. Prior to that, he held the position of Director, Clinical Research at Novartis Pharma AG in Basle, Switzerland. Dr. Pearce received his M.D. from the Medical College of Georgia and is board-certified in both internal medicine and hematology.


JOEL A. FERNANDES, C.P.A

SENIOR VICE PRESIDENT, FINANCE AND CONTROLLER

Joel Fernandes was appointed Threshold's Senior Vice President, Finance and Controller in March 2016. Previously, he served as Threshold's Vice President, Finance and Controller since May 2011 having held roles of increasing responsibility in finance and accounting since joining the company in 2006. Prior to joining Threshold, Mr. Fernandes served as Associate Director of Finance at Theravance Inc., Senior Manager of Corporate Finance at KLA-Tencor, and Assistant Controller of ALZA Corporation. Mr. Fernandes holds a CPA and a Masters in Accountancy from Manchester College, Indiana.


CHARLES P. HART, PH.D.

SENIOR VICE PRESIDENT, BIOLOGY

Charles Hart, Ph.D., was appointed Threshold’s Vice President, Biology in 2008. He joined the company as Senior Director, Biology in 2004. Dr. Hart is responsible for in vitro and in vivo preclinical translational studies. Prior to joining Threshold, Dr. Hart was Senior Director, Biology at Galileo Pharmaceuticals, Director of Drug Discovery at Signature Bioscience, and a Research Unit Director at Affymax (a Glaxo company). Dr. Hart holds an A.B. from UC Berkeley, an M.S. from Stanford University, and a Ph.D. in Molecular Biology and Genetics from Yale University. Dr. Hart completed a postdoctoral fellowship at the University of Strasbourg, France.


ERIC D. MALEK, M.B.A.

SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT

Eric Malek was appointed Threshold's Senior Vice President, Corporate Development in March 2016. Mr. Malek joined Threshold as Vice President, Corporate Development in 2010 and led negotiations for the TH-302 co-development and co-commercialization partnership with Merck KGaA. Prior to joining Threshold, he led corporate development at BiPar Sciences where he initiated the partnering effort that led to BiPar's acquisition by Sanofi-Aventis. Prior to BiPar, Mr. Malek was Vice President, Corporate Development at Allos Therapeutics, where he led the acquisition and product planning efforts for FOLOTYN®, indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Before Allos, Mr. Malek held business development positions at Gilead Sciences, NeXstar Pharmaceuticals, Ilex Oncology and Research Corporation Technologies as well as research positions at Janssen Pharmaceuticals. Mr. Malek holds a B.A. in Biochemistry from the University of Arizona and an M.B.A. from the University of Michigan.


MARK HOPKINS, J.D., PH.D.

Vice President of Intellectual Property and Assistant General Counsel

Mark Hopkins, J.D., Ph.D., joined Threshold as Vice President of Intellectual Property and Assistant General Counsel in July 2015. Dr. Hopkins is responsible for advising the company on a variety of legal issues both domestically and internationally. Dr. Hopkins has more than 16 years of legal experience in the pharmaceutical industry. Prior to joining Threshold, Dr. Hopkins was a partner at Kilpatrick Townsend and Stockton LLP where he led a team of legal professionals providing legal opinions and securing patents for pharmaceutical companies on their key drugs. Dr. Hopkins began his career as a senior scientist and patent agent with the Dow Chemical Company, where he led a multidisciplinary team responsible for lead generation in several novel chemical applications. Dr. Hopkins was an American Cancer Society postdoctoral fellow at Northwestern University, has a J.D. from the John Marshall Law School, a Ph.D. in Chemistry from the University of California, Irvine, and is the author of multiple legal and scientific publications.


Kristen Quigley, B.A.

Vice President of Clinical Operations

Kristen Quigley was appointed Vice President of Clinical Operations in October 2016. Ms. Quigley has over 20 years of experience in the pharmaceutical/CRO industry in both Europe and the United States. She joined Threshold in June 2014 as Senior Director of Clinical Operations, leading cross-functional process-improvement initiatives and several successful CRO collaborations on the TH-302 program. Prior to joining Threshold, Ms. Quigley held various Project Management and Clinical Trial Management roles during a 12-year tenure with ICON Clinical Research, the most recent of which was Project Management Senior Director in ICON's Oncology and Hematology Division From 2013-2014. Between 2010-2011, Ms. Quigley was stationed in Stockholm, Sweden as co-Director of ICON's Nordic region. Prior to joining ICON, she held Project Management and Clinical Research Associate roles during a 5-year tenure at Kendle International. Kristen received her B.A. from Washington University in St. Louis.